{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:54:35Z","timestamp":1795042475069,"version":"4.10.2"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"43","license":[{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>Individuals with tuberculosis (TB) who are being treated with anti-tumor necrosis factor \u03b1 (anti-TNF\u03b1) for coexisting conditions may experience unexpected exacerbations of TB after the initiation of antituberculous therapy, so-called anti-TNF\u03b1-induced TB-immune reconstitution inflammatory syndrome (anti-TNF\u03b1-induced TB-IRIS). Anti-TNF\u03b1-induced TB-IRIS is often treated empirically with corticosteroids; however, the evidence of the effectiveness of corticosteroids is lacking and the management can be a challenge.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 32-year-old man on long-term infliximab therapy for Crohn disease visited a clinic complaining of persistent fever and cough that had started 1 week previously. His most recent infliximab injection had been administered 14 days before the visit. A chest X-ray revealed a left pleural effusion, and he was admitted to a local hospital.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>A chest computed tomography (CT) scan revealed miliary pulmonary nodules; acid-fast bacilli were found in a sputum smear and a urine sediment sample; and polymerase chain reaction confirmed the presence of <jats:italic toggle=\"yes\">Mycobacterium tuberculosis<\/jats:italic> in both his sputum and the pleural effusion. He was diagnosed with miliary TB.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Antituberculous therapy was started and he was transferred to our hospital for further management. His symptoms initially improved after the initiation of antituberculous therapy, but 2 weeks later, his symptoms recurred and shadows on chest X-ray worsened. A repeat chest CT scan revealed enlarged miliary pulmonary nodules, extensive ground-glass opacities, and an increased volume of his pleural effusion. This paradoxical exacerbation was diagnosed as TB-IRIS associated with infliximab. A moderate-dose of systemic corticosteroid was initiated [prednisolone 25\u200amg\/day (0.5\u200amg\/kg\/day)].<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>After starting corticosteroid treatment, his radiological findings improved immediately, and his fever and cough disappeared within a few days. After discharge, prednisolone was tapered off over the course of 10 weeks, and he completed a 9-month course of antituberculous therapy uneventfully. He had not restarted infliximab at his most recent follow-up 14 months later.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>We successfully managed a patient with anti-TNF\u03b1-induced TB-IRIS using moderate-dose corticosteroids. Due to the limited evidence currently available, physicians should consider the necessity, dosage, and duration of corticosteroids for each case of anti-TNF\u03b1-induced TB-IRIS on an individual patient-by-patient basis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000022076","type":"journal-article","created":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T01:05:29Z","timestamp":1603501529000},"page":"e22076","source":"Crossref","is-referenced-by-count":7,"title":["Use of steroids to treat anti-tumor necrosis factor \u03b1 induced tuberculosis-associated immune reconstitution inflammatory syndrome"],"prefix":"10.1097","volume":"99","author":[{"given":"Daijiro","family":"Nabeya","sequence":"first","affiliation":[{"name":"Department of Infectious, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus"},{"name":"Department of Respiratory Medicine, Okinawa Chubu Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0262-0401","authenticated-orcid":false,"given":"Takeshi","family":"Kinjo","sequence":"additional","affiliation":[{"name":"Department of Infectious, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Yamaniha","sequence":"additional","affiliation":[{"name":"Department of Infectious, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoshin","family":"Yamazato","sequence":"additional","affiliation":[{"name":"Department of Infectious, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reo","family":"Tome","sequence":"additional","affiliation":[{"name":"Department of Infectious, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Miyagi","sequence":"additional","affiliation":[{"name":"Department of Infectious, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideta","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Infectious, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsu","family":"Kinjo","sequence":"additional","affiliation":[{"name":"Department of Infectious, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusaku","family":"Haranaga","sequence":"additional","affiliation":[{"name":"Department of Infectious, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Futoshi","family":"Higa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Hospital Organization Okinawa National Hospital, Okinawa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiro","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Infectious, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,10,23]]},"reference":[{"key":"R1-20230916","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1086\/427941","article-title":"Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis","volume":"40","author":"Garcia Vidal","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R2-20230916","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00003495-200868020-00004","article-title":"Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy: pathogenesis, clinical manifestations and management","volume":"68","author":"Dhasmana","year":"2008","journal-title":"Drugs"},{"key":"R3-20230916","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jbspin.2015.04.022","article-title":"Paradoxical anti-TNF-associated TB worsening: frequency and factors associated with IRIS","volume":"83","author":"Rivoisy","year":"2016","journal-title":"Joint Bone Spine"},{"key":"R4-20230916","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2217\/fmb.15.9","article-title":"Paradoxical TB-IRIS in HIV-infected adults: a systematic review and meta-analysis","volume":"10","author":"Namale","year":"2015","journal-title":"Future Microbiol"},{"key":"R5-20230916","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/01.aids.0000202648.18526.bf","article-title":"Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients","volume":"20","author":"Bourgarit","year":"2006","journal-title":"AIDS"},{"key":"R6-20230916","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/QCO.0b013e32832d7aff","article-title":"Immune reconstitution inflammatory syndrome in non-HIV immunocompromised patients","volume":"22","author":"Sun","year":"2009","journal-title":"Curr Opin Infect Dis"},{"key":"R7-20230916","first-page":"1057","article-title":"Immune reconstitution to Mycobacterium tuberculosis after discontinuing infliximab","volume":"9","author":"Belknap","year":"2005","journal-title":"Int J Tuberc Lung Dis"},{"key":"R8-20230916","doi-asserted-by":"crossref","first-page":"6673","DOI":"10.1186\/1752-1947-3-6673","article-title":"Paradoxical response during antituberculous therapy in a patient discontinuing infliximab: a case report","volume":"3","author":"Yoon","year":"2009","journal-title":"J Med Case Rep"},{"key":"R9-20230916","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jbspin.2011.01.003","article-title":"Paradoxical exacerbation of tuberculosis after TNF\u03b1 antagonist discontinuation: beware of immune reconstitution inflammatory syndrome","volume":"78","author":"Rivoisy","year":"2011","journal-title":"Joint Bone Spine"},{"key":"R10-20230916","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.amjmed.2012.02.006","article-title":"Paradoxical response to tuberculosis treatment in a patient receiving tumor necrosis factor-alpha antagonist","volume":"125","author":"Moureau","year":"2012","journal-title":"Am J Med"},{"key":"R11-20230916","first-page":"43","article-title":"Disseminated tuberculosis infection and paradoxical reaction during antimycobacterial treatment related to TNF-alpha blocker agent Infliximab","volume":"13","author":"Unlu","year":"2014","journal-title":"Respir Med Case Rep"},{"key":"R12-20230916","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1086\/522993","article-title":"A patient with de novo tuberculosis during anti-tumor necrosis factor-alpha therapy illustrating diagnostic pitfalls and paradoxical response to treatment","volume":"45","author":"Arend","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R13-20230916","first-page":"201","article-title":"Paradoxical response with increased tumor necrosis factor-( levels to anti-tuberculosis treatment in a patient with disseminated tuberculosis","volume":"20","author":"Watanabe","year":"2017","journal-title":"Respir Med Case Rep"},{"key":"R14-20230916","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s00431-011-1501-y","article-title":"Life-threatening disseminated tuberculosis as a complication of TNF-\u03b1 blockade in an adolescent","volume":"170","author":"Hess","year":"2011","journal-title":"Eur J Pediatr"},{"key":"R15-20230916","first-page":"39","article-title":"Prolonged paradoxical reaction to anti-tuberculous treatment after discontinuation of TNF-alpha- blocker therapy with adalimumab","volume":"10","author":"Falkenstern-Ge","year":"2015","journal-title":"Open Med (Wars)"},{"key":"R16-20230916","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2169\/internalmedicine.54.2828","article-title":"Central nervous system manifestations of tuberculosis-associated immune reconstitution inflammatory syndrome during adalimumab therapy: a case report and review of the literature","volume":"54","author":"Tanaka","year":"2015","journal-title":"Intern Med"},{"key":"R17-20230916","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/RHU.0b013e3181bc9407","article-title":"Peritoneal tuberculosis complicated by immune reconstitution inflammatory syndrome in a patient treated with infliximab? A case for adjuvant immunosuppressive therapy","volume":"15","author":"Szerszen","year":"2009","journal-title":"J Clin Rheumatol"},{"key":"R18-20230916","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11096-010-9369-x","article-title":"Haemophagocytic syndrome and paradoxical reaction to tuberculostatics after treatment with infliximab","volume":"32","author":"Troncoso Mari\u00f1o","year":"2010","journal-title":"Pharm World Sci"},{"issue":"(suppl 3)","key":"R19-20230916","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1016\/j.ijid.2010.03.002","article-title":"Prolonged paradoxical response to anti-tuberculous treatment after infliximab","volume":"14","author":"Melboucy-Belkhir","year":"2010","journal-title":"Int J Infect Dis"},{"key":"R20-20230916","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1086\/598504","article-title":"Adalimumab treatment of life-threatening tuberculosis","volume":"48","author":"Wallis","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R21-20230916","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/RHU.0b013e318258b725","article-title":"A life-threatening central nervous system-tuberculosis inflammatory reaction nonresponsive to corticosteroids and successfully controlled by infliximab in a young patient with a variant of juvenile idiopathic arthritis","volume":"18","author":"Jorge","year":"2012","journal-title":"J Clin Rheumatol"},{"key":"R22-20230916","first-page":"147","article-title":"Re-administration of abatacept for the control of articular symptoms of rheumatoid arthritis during anti-tuberculous therapy","volume":"21","author":"Kawamoto","year":"2017","journal-title":"Respir Med Case Rep"},{"key":"R23-20230916","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1183\/09031936.00070907","article-title":"Pulmonary tuberculosis with acute respiratory failure","volume":"32","author":"Kim","year":"2008","journal-title":"Eur Respir J"},{"key":"R24-20230916","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1093\/cid\/ciw616","article-title":"Effects of corticosteroids on critically ill pulmonary tuberculosis patients with acute respiratory failure: a propensity analysis of mortality","volume":"63","author":"Yang","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"(RR-11)","key":"R25-20230916","first-page":"1","article-title":"Infectious Diseases Society of America. Treatment of tuberculosis","volume":"52","year":"2003","journal-title":"MMWR Recomm Rep"},{"key":"R26-20230916","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1164\/ajrccm.158.1.9712001","article-title":"Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS","volume":"158","author":"Narita","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"R27-20230916","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/clinids\/11.6.954","article-title":"Risk of infectious complications in patients taking glucocorticosteroids","volume":"11","author":"Stuck","year":"1989","journal-title":"Rev Infect Dis"},{"key":"R28-20230916","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1473-3099(12)70321-3","article-title":"Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis","volume":"13","author":"Critchley","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"R29-20230916","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1086\/592695","article-title":"Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes","volume":"47","author":"Blackmore","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R30-20230916","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10156-011-0334-y","article-title":"Adalimumab treatment may replace or enhance the activity of steroids in steroid-refractory tuberculous meningitis","volume":"18","author":"Lee","year":"2012","journal-title":"J Infect Chemother"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022076","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T03:52:11Z","timestamp":1694836331000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022076"}},"subtitle":["Case report and literature review"],"short-title":[],"issued":{"date-parts":[[2020,10,23]]},"references-count":30,"journal-issue":{"issue":"43","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000022076","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,23]]}}}